To assess the clinical relevance of NTRK2 activation and PTEN, we analyzed gene expression data [4] from a panel of T-ALL cell lines in the Oncomine Database (Oncomine), and found that the levels of the NTRK2 transcript were consistently higher in PTEN-deficient T-ALL cell lines compared with PTEN wild-type cells (Figure 2a). This evidence concerns the gene NTRK2 and acute lymphoblastic leukemia.